Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning, you’ve made it Friday! We’ve got some more news to get through before heading into the weekend.
FDA delivers split decision on GSK’s Blenrep
The Food and Drug Administration yesterday delivered a split decision on GSK’s blood cancer drug Blenrep, approving its use in combination with a medicine called Velcade, but rejecting it when used with a different treatment called Pomalyst.
Continue to STAT+ to read the full story…
STAT Pharma: The science and business of new drug development
Leave a Reply